Safety and Tolerability Study of Combination Nivolumab and Cabiralizumab as Neoadjuvant and Adjuvant Therapy for Resectable Biliary Tract Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary)
- Indications Biliary cancer
- Focus Adverse reactions
- 07 Aug 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jun 2019 to 1 Sep 2019.
- 05 Jul 2019 Status changed from not yet recruiting to recruiting.
- 04 Jun 2019 Planned initiation date changed from 1 May 2019 to 1 Jun 2019.